| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 6 | 2023 | 48 | 4.570 |
Why?
|
| Glaucoma, Open-Angle | 6 | 2024 | 42 | 4.530 |
Why?
|
| Diabetic Retinopathy | 7 | 2023 | 43 | 3.880 |
Why?
|
| Macular Degeneration | 7 | 2024 | 176 | 3.570 |
Why?
|
| Telemedicine | 6 | 2024 | 333 | 2.970 |
Why?
|
| Intraocular Pressure | 7 | 2024 | 61 | 2.910 |
Why?
|
| Diabetes Mellitus | 17 | 2023 | 533 | 2.870 |
Why?
|
| Tomography, Optical Coherence | 8 | 2024 | 199 | 2.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 18 | 2023 | 211 | 2.160 |
Why?
|
| Veterans | 22 | 2023 | 722 | 1.840 |
Why?
|
| Visual Acuity | 7 | 2024 | 111 | 1.760 |
Why?
|
| Wet Macular Degeneration | 2 | 2023 | 23 | 1.720 |
Why?
|
| Retinal Vein Occlusion | 2 | 2024 | 18 | 1.710 |
Why?
|
| Atherosclerosis | 10 | 2023 | 147 | 1.600 |
Why?
|
| Ophthalmology | 4 | 2022 | 23 | 1.520 |
Why?
|
| Cardiovascular Diseases | 15 | 2023 | 827 | 1.470 |
Why?
|
| Humans | 114 | 2024 | 59280 | 1.390 |
Why?
|
| Geographic Atrophy | 2 | 2024 | 20 | 1.350 |
Why?
|
| Ranibizumab | 4 | 2023 | 20 | 1.340 |
Why?
|
| Fluorescein Angiography | 4 | 2024 | 51 | 1.330 |
Why?
|
| Smartphone | 2 | 2021 | 61 | 1.320 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 3 | 2021 | 14 | 1.300 |
Why?
|
| Dark Adaptation | 3 | 2019 | 8 | 1.240 |
Why?
|
| Intravitreal Injections | 5 | 2023 | 47 | 1.210 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2023 | 78 | 1.160 |
Why?
|
| Visual Fields | 3 | 2024 | 42 | 1.140 |
Why?
|
| Nerve Fibers | 2 | 2024 | 29 | 1.120 |
Why?
|
| Cross-Sectional Studies | 22 | 2024 | 2461 | 1.080 |
Why?
|
| Optic Nerve Diseases | 2 | 2024 | 19 | 1.010 |
Why?
|
| Papilledema | 2 | 2022 | 10 | 0.990 |
Why?
|
| Retinal Diseases | 2 | 2024 | 30 | 0.990 |
Why?
|
| Microaneurysm | 2 | 2023 | 2 | 0.980 |
Why?
|
| Aged | 52 | 2024 | 13285 | 0.950 |
Why?
|
| Medical Tourism | 1 | 2024 | 1 | 0.930 |
Why?
|
| Lasers, Solid-State | 1 | 2024 | 8 | 0.920 |
Why?
|
| Eye Injuries | 1 | 2024 | 14 | 0.920 |
Why?
|
| Laser Therapy | 1 | 2024 | 36 | 0.900 |
Why?
|
| Female | 65 | 2024 | 30797 | 0.890 |
Why?
|
| Middle Aged | 57 | 2024 | 16230 | 0.880 |
Why?
|
| Retinal Ganglion Cells | 3 | 2024 | 26 | 0.860 |
Why?
|
| Retinal Detachment | 1 | 2023 | 17 | 0.860 |
Why?
|
| Hepatitis C, Chronic | 8 | 2016 | 88 | 0.840 |
Why?
|
| Photography | 2 | 2021 | 43 | 0.820 |
Why?
|
| Cone-Rod Dystrophies | 1 | 2022 | 1 | 0.820 |
Why?
|
| Barrett Esophagus | 8 | 2014 | 34 | 0.810 |
Why?
|
| Retinal Vein | 1 | 2022 | 5 | 0.810 |
Why?
|
| Retinitis Pigmentosa | 1 | 2022 | 25 | 0.800 |
Why?
|
| Hemifacial Spasm | 1 | 2022 | 2 | 0.800 |
Why?
|
| Retinal Degeneration | 1 | 2022 | 30 | 0.800 |
Why?
|
| Retina | 4 | 2022 | 118 | 0.790 |
Why?
|
| Bell Palsy | 1 | 2022 | 7 | 0.790 |
Why?
|
| Facial Paralysis | 1 | 2022 | 12 | 0.780 |
Why?
|
| Night Blindness | 1 | 2021 | 1 | 0.770 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2021 | 1 | 0.770 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2021 | 2 | 0.770 |
Why?
|
| Patient Satisfaction | 4 | 2021 | 413 | 0.770 |
Why?
|
| Male | 68 | 2024 | 27478 | 0.760 |
Why?
|
| Retrospective Studies | 16 | 2024 | 5966 | 0.740 |
Why?
|
| Macular Pigment | 1 | 2020 | 2 | 0.720 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 675 | 0.720 |
Why?
|
| Healthcare Disparities | 6 | 2023 | 330 | 0.650 |
Why?
|
| Optic Nerve | 4 | 2023 | 28 | 0.650 |
Why?
|
| Veterans Health | 7 | 2023 | 156 | 0.630 |
Why?
|
| Risk Factors | 20 | 2024 | 4997 | 0.620 |
Why?
|
| Adult | 34 | 2024 | 15728 | 0.610 |
Why?
|
| Liver Cirrhosis | 6 | 2016 | 160 | 0.600 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 266 | 0.590 |
Why?
|
| Dyslipidemias | 4 | 2020 | 34 | 0.580 |
Why?
|
| Medication Adherence | 5 | 2021 | 255 | 0.570 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2020 | 712 | 0.550 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2023 | 112 | 0.530 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 201 | 0.520 |
Why?
|
| United States | 29 | 2023 | 7491 | 0.510 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 2323 | 0.500 |
Why?
|
| Hypoxia | 1 | 2015 | 107 | 0.480 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 386 | 0.470 |
Why?
|
| Physician Assistants | 3 | 2021 | 37 | 0.470 |
Why?
|
| Eyeglasses | 1 | 2014 | 7 | 0.460 |
Why?
|
| Presbyopia | 1 | 2014 | 2 | 0.460 |
Why?
|
| Rod Opsins | 1 | 2013 | 4 | 0.450 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2021 | 249 | 0.450 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2023 | 32 | 0.440 |
Why?
|
| Nurse Practitioners | 3 | 2021 | 115 | 0.440 |
Why?
|
| Visual Field Tests | 2 | 2024 | 22 | 0.440 |
Why?
|
| Vision, Ocular | 1 | 2013 | 18 | 0.440 |
Why?
|
| Bevacizumab | 3 | 2023 | 56 | 0.440 |
Why?
|
| Pandemics | 3 | 2023 | 606 | 0.430 |
Why?
|
| Dementia | 3 | 2021 | 247 | 0.430 |
Why?
|
| Peripheral Arterial Disease | 4 | 2020 | 152 | 0.420 |
Why?
|
| Retinal Vessels | 3 | 2023 | 17 | 0.420 |
Why?
|
| Risk Assessment | 10 | 2024 | 1907 | 0.410 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2023 | 502 | 0.390 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 5063 | 0.390 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 70 | 0.390 |
Why?
|
| Retinal Bipolar Cells | 2 | 2011 | 4 | 0.380 |
Why?
|
| Patient Compliance | 3 | 2023 | 371 | 0.380 |
Why?
|
| United States Department of Veterans Affairs | 8 | 2021 | 511 | 0.370 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 53 | 0.370 |
Why?
|
| Receptors, GABA | 2 | 2007 | 12 | 0.360 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 636 | 0.360 |
Why?
|
| Hyperparathyroidism, Primary | 2 | 2020 | 7 | 0.350 |
Why?
|
| Ethics Committees, Clinical | 1 | 2010 | 5 | 0.350 |
Why?
|
| Ethics Consultation | 1 | 2010 | 3 | 0.350 |
Why?
|
| Pilot Projects | 3 | 2019 | 917 | 0.350 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 2584 | 0.340 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 370 | 0.340 |
Why?
|
| Hypertension | 6 | 2022 | 600 | 0.340 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 421 | 0.330 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 197 | 0.330 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2007 | 195 | 0.330 |
Why?
|
| Travel | 1 | 2009 | 31 | 0.320 |
Why?
|
| Laryngeal Neoplasms | 4 | 2013 | 53 | 0.320 |
Why?
|
| Disease Progression | 3 | 2023 | 1039 | 0.320 |
Why?
|
| Hypercholesterolemia | 2 | 2019 | 68 | 0.310 |
Why?
|
| Diarrhea | 1 | 2009 | 73 | 0.310 |
Why?
|
| Physicians, Primary Care | 2 | 2021 | 72 | 0.300 |
Why?
|
| Virus Diseases | 1 | 2009 | 110 | 0.300 |
Why?
|
| Global Health | 1 | 2009 | 161 | 0.290 |
Why?
|
| Fundus Oculi | 2 | 2024 | 17 | 0.290 |
Why?
|
| Bacterial Infections | 1 | 2009 | 139 | 0.290 |
Why?
|
| Lipids | 2 | 2019 | 305 | 0.280 |
Why?
|
| Ambulatory Care | 3 | 2018 | 299 | 0.280 |
Why?
|
| Cholesterol, LDL | 4 | 2021 | 105 | 0.280 |
Why?
|
| Electroretinography | 2 | 2022 | 26 | 0.270 |
Why?
|
| Electrophysiology | 1 | 2006 | 89 | 0.270 |
Why?
|
| Sex Factors | 9 | 2022 | 959 | 0.270 |
Why?
|
| Helicobacter Infections | 3 | 2015 | 55 | 0.260 |
Why?
|
| Primary Health Care | 7 | 2023 | 645 | 0.260 |
Why?
|
| Internet | 1 | 2010 | 457 | 0.260 |
Why?
|
| Interleukins | 3 | 2015 | 77 | 0.260 |
Why?
|
| Hypoglycemic Agents | 4 | 2022 | 211 | 0.250 |
Why?
|
| Obesity | 5 | 2019 | 1189 | 0.250 |
Why?
|
| Myocardial Ischemia | 3 | 2021 | 108 | 0.240 |
Why?
|
| Guideline Adherence | 5 | 2019 | 295 | 0.240 |
Why?
|
| Secondary Prevention | 3 | 2021 | 152 | 0.240 |
Why?
|
| Substance-Related Disorders | 2 | 2023 | 689 | 0.240 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2024 | 3 | 0.230 |
Why?
|
| Brain Ischemia | 2 | 2020 | 403 | 0.230 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 1546 | 0.230 |
Why?
|
| Treatment Outcome | 8 | 2023 | 5140 | 0.230 |
Why?
|
| Light | 2 | 2015 | 201 | 0.220 |
Why?
|
| Precancerous Conditions | 2 | 2014 | 72 | 0.220 |
Why?
|
| Adiposity | 2 | 2016 | 81 | 0.220 |
Why?
|
| Caregivers | 3 | 2021 | 216 | 0.220 |
Why?
|
| Lacerations | 1 | 2023 | 16 | 0.220 |
Why?
|
| Cornea | 1 | 2023 | 19 | 0.220 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2023 | 26 | 0.210 |
Why?
|
| Aggression | 2 | 2021 | 57 | 0.210 |
Why?
|
| Diet, Mediterranean | 1 | 2023 | 32 | 0.210 |
Why?
|
| Multivariate Analysis | 8 | 2021 | 926 | 0.210 |
Why?
|
| Quality of Health Care | 2 | 2018 | 519 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 484 | 0.210 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 253 | 0.210 |
Why?
|
| Pseudotumor Cerebri | 1 | 2022 | 10 | 0.210 |
Why?
|
| Blood Pressure | 4 | 2019 | 519 | 0.210 |
Why?
|
| Telephone | 1 | 2023 | 121 | 0.210 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 1024 | 0.210 |
Why?
|
| Bacteriuria | 1 | 2022 | 11 | 0.200 |
Why?
|
| Ischemia | 1 | 2024 | 190 | 0.200 |
Why?
|
| Antimicrobial Stewardship | 1 | 2022 | 14 | 0.200 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2023 | 71 | 0.200 |
Why?
|
| Public Health | 1 | 2024 | 180 | 0.200 |
Why?
|
| Odds Ratio | 7 | 2020 | 772 | 0.200 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 451 | 0.200 |
Why?
|
| Methylprednisolone | 1 | 2021 | 30 | 0.200 |
Why?
|
| Regression Analysis | 4 | 2019 | 485 | 0.200 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2022 | 45 | 0.190 |
Why?
|
| Tonometry, Ocular | 1 | 2021 | 15 | 0.190 |
Why?
|
| Problem Behavior | 1 | 2021 | 12 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2022 | 387 | 0.180 |
Why?
|
| Parathyroidectomy | 1 | 2020 | 6 | 0.180 |
Why?
|
| Rheumatic Fever | 1 | 2020 | 3 | 0.180 |
Why?
|
| Liver Diseases | 2 | 2012 | 137 | 0.180 |
Why?
|
| Case-Control Studies | 8 | 2014 | 1058 | 0.180 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2022 | 152 | 0.180 |
Why?
|
| Microvessels | 1 | 2020 | 17 | 0.180 |
Why?
|
| Wounds and Injuries | 1 | 2003 | 234 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2022 | 2435 | 0.180 |
Why?
|
| Pain | 2 | 2021 | 406 | 0.170 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 263 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 869 | 0.170 |
Why?
|
| Samoa | 1 | 2019 | 3 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 542 | 0.170 |
Why?
|
| Prospective Studies | 5 | 2019 | 3095 | 0.170 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 72 | 0.160 |
Why?
|
| Operating Rooms | 1 | 2019 | 53 | 0.160 |
Why?
|
| Echocardiography, Stress | 1 | 2019 | 13 | 0.160 |
Why?
|
| Vaccination | 1 | 2021 | 337 | 0.160 |
Why?
|
| Anxiety Disorders | 3 | 2018 | 188 | 0.160 |
Why?
|
| Logistic Models | 7 | 2018 | 1252 | 0.160 |
Why?
|
| Aspirin | 1 | 2020 | 186 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 156 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 151 | 0.160 |
Why?
|
| Thinness | 1 | 2019 | 39 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 462 | 0.160 |
Why?
|
| Diabetic Nephropathies | 1 | 2018 | 38 | 0.150 |
Why?
|
| Psyllium | 1 | 2018 | 5 | 0.150 |
Why?
|
| Young Adult | 4 | 2022 | 4318 | 0.150 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 50 | 0.150 |
Why?
|
| Religion | 1 | 2018 | 33 | 0.150 |
Why?
|
| Spirituality | 1 | 2018 | 47 | 0.150 |
Why?
|
| Texas | 4 | 2020 | 54 | 0.150 |
Why?
|
| Consumer Behavior | 1 | 2018 | 35 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2022 | 385 | 0.150 |
Why?
|
| Cryotherapy | 2 | 2008 | 12 | 0.150 |
Why?
|
| Coronary Disease | 2 | 2016 | 249 | 0.150 |
Why?
|
| Blood Glucose | 2 | 2017 | 470 | 0.150 |
Why?
|
| Cyclin A | 2 | 2008 | 8 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2021 | 408 | 0.150 |
Why?
|
| Cyclin E | 2 | 2008 | 14 | 0.150 |
Why?
|
| Exercise Test | 1 | 2019 | 233 | 0.140 |
Why?
|
| Hernia, Hiatal | 2 | 2014 | 26 | 0.140 |
Why?
|
| Trust | 1 | 2018 | 66 | 0.140 |
Why?
|
| Heart Failure | 2 | 2023 | 861 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2019 | 891 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 1 | 2019 | 245 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 2 | 2014 | 77 | 0.140 |
Why?
|
| cdc25 Phosphatases | 2 | 2007 | 6 | 0.140 |
Why?
|
| Medicine | 2 | 2014 | 56 | 0.140 |
Why?
|
| Amino Acids | 1 | 2018 | 140 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2018 | 278 | 0.140 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2016 | 42 | 0.140 |
Why?
|
| Psychometrics | 1 | 2019 | 355 | 0.140 |
Why?
|
| Animals | 7 | 2023 | 19595 | 0.140 |
Why?
|
| Patch-Clamp Techniques | 2 | 2007 | 125 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2016 | 576 | 0.130 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2016 | 4 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 172 | 0.130 |
Why?
|
| Anxiety | 1 | 2019 | 395 | 0.130 |
Why?
|
| Smoking | 3 | 2016 | 830 | 0.130 |
Why?
|
| Haplotypes | 1 | 2016 | 117 | 0.130 |
Why?
|
| Age Factors | 5 | 2020 | 1518 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 40 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 102 | 0.130 |
Why?
|
| Mortality | 1 | 2016 | 159 | 0.130 |
Why?
|
| Time Factors | 6 | 2020 | 3567 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2008 | 233 | 0.120 |
Why?
|
| Hepacivirus | 2 | 2013 | 140 | 0.120 |
Why?
|
| Coffee | 1 | 2015 | 19 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 248 | 0.120 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 199 | 0.120 |
Why?
|
| Caffeine | 1 | 2015 | 47 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 192 | 0.120 |
Why?
|
| Eye Infections, Bacterial | 1 | 2014 | 5 | 0.120 |
Why?
|
| Retinoblastoma | 1 | 2014 | 27 | 0.120 |
Why?
|
| Endophthalmitis | 1 | 2014 | 11 | 0.120 |
Why?
|
| Receptors, Calcitriol | 1 | 2014 | 32 | 0.120 |
Why?
|
| Optic Disk | 1 | 2014 | 24 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 298 | 0.120 |
Why?
|
| Fovea Centralis | 1 | 2014 | 17 | 0.120 |
Why?
|
| Esophagus | 1 | 2014 | 51 | 0.120 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 77 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 2015 | 102 | 0.120 |
Why?
|
| Psychotherapy | 1 | 2015 | 89 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2014 | 74 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2018 | 443 | 0.120 |
Why?
|
| Philippines | 1 | 2014 | 5 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 677 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1093 | 0.110 |
Why?
|
| Quality of Life | 2 | 2014 | 1108 | 0.110 |
Why?
|
| Esophagoscopy | 1 | 2013 | 27 | 0.110 |
Why?
|
| Oxygen | 1 | 2015 | 307 | 0.110 |
Why?
|
| Stroke | 1 | 2022 | 1135 | 0.110 |
Why?
|
| Metformin | 1 | 2014 | 67 | 0.110 |
Why?
|
| Adipokines | 1 | 2013 | 28 | 0.110 |
Why?
|
| Diphosphonates | 1 | 2013 | 34 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 71 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 446 | 0.110 |
Why?
|
| Bone Density Conservation Agents | 1 | 2013 | 48 | 0.110 |
Why?
|
| Rats | 2 | 2007 | 1907 | 0.110 |
Why?
|
| Hepatitis | 1 | 2013 | 55 | 0.110 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 76 | 0.110 |
Why?
|
| Ki-67 Antigen | 3 | 2008 | 34 | 0.110 |
Why?
|
| Fructose | 1 | 2013 | 40 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 77 | 0.100 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 11 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2014 | 154 | 0.100 |
Why?
|
| Depression | 1 | 2020 | 857 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 456 | 0.100 |
Why?
|
| Air Pollutants, Occupational | 1 | 2013 | 76 | 0.100 |
Why?
|
| Finasteride | 1 | 2012 | 5 | 0.100 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 846 | 0.100 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 7 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 314 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 202 | 0.100 |
Why?
|
| Overweight | 1 | 2014 | 247 | 0.100 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2013 | 141 | 0.100 |
Why?
|
| Physicians | 1 | 2017 | 436 | 0.100 |
Why?
|
| Narcotics | 1 | 2012 | 50 | 0.100 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 20 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2013 | 137 | 0.100 |
Why?
|
| Rural Population | 1 | 2014 | 191 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 810 | 0.100 |
Why?
|
| Drug Prescriptions | 3 | 2020 | 188 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2013 | 274 | 0.090 |
Why?
|
| Methadone | 1 | 2012 | 126 | 0.090 |
Why?
|
| TRPM Cation Channels | 1 | 2011 | 12 | 0.090 |
Why?
|
| Depressive Disorder | 2 | 2018 | 291 | 0.090 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1470 | 0.090 |
Why?
|
| Testosterone | 1 | 2011 | 118 | 0.090 |
Why?
|
| Incidence | 3 | 2021 | 1232 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2013 | 264 | 0.090 |
Why?
|
| Biomarkers | 4 | 2019 | 1205 | 0.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 365 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2012 | 139 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2014 | 943 | 0.090 |
Why?
|
| Autoantibodies | 1 | 2011 | 174 | 0.090 |
Why?
|
| Endoscopy, Digestive System | 3 | 2014 | 30 | 0.090 |
Why?
|
| Proteins | 1 | 2016 | 742 | 0.090 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 1447 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2013 | 306 | 0.080 |
Why?
|
| Cytokines | 1 | 2013 | 906 | 0.080 |
Why?
|
| Cause of Death | 2 | 2016 | 200 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 106 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2014 | 254 | 0.080 |
Why?
|
| Algorithms | 1 | 2014 | 986 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2017 | 837 | 0.080 |
Why?
|
| Registries | 2 | 2022 | 802 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2008 | 52 | 0.070 |
Why?
|
| Cell Shape | 1 | 2007 | 13 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 334 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 704 | 0.070 |
Why?
|
| Mood Disorders | 1 | 2007 | 69 | 0.070 |
Why?
|
| Oscillometry | 1 | 2006 | 12 | 0.070 |
Why?
|
| Rats, Long-Evans | 1 | 2006 | 21 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 36 | 0.070 |
Why?
|
| Adolescent | 4 | 2018 | 5914 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2007 | 79 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 672 | 0.070 |
Why?
|
| Photic Stimulation | 1 | 2006 | 90 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 525 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 450 | 0.060 |
Why?
|
| Poland | 2 | 2016 | 7 | 0.060 |
Why?
|
| Prognosis | 4 | 2014 | 1564 | 0.060 |
Why?
|
| Prevalence | 2 | 2022 | 1279 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2016 | 131 | 0.060 |
Why?
|
| Helicobacter pylori | 2 | 2015 | 58 | 0.060 |
Why?
|
| Waist-Hip Ratio | 2 | 2014 | 14 | 0.060 |
Why?
|
| Proton Pump Inhibitors | 2 | 2014 | 39 | 0.060 |
Why?
|
| Interferons | 2 | 2015 | 64 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2020 | 384 | 0.060 |
Why?
|
| Life Cycle Stages | 1 | 2023 | 14 | 0.060 |
Why?
|
| Face | 1 | 2023 | 34 | 0.050 |
Why?
|
| Autophagy | 2 | 2016 | 205 | 0.050 |
Why?
|
| Accidents | 1 | 2003 | 12 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 847 | 0.050 |
Why?
|
| Homicide | 1 | 2003 | 25 | 0.050 |
Why?
|
| Pakistan | 1 | 2022 | 14 | 0.050 |
Why?
|
| Prescriptions | 1 | 2023 | 33 | 0.050 |
Why?
|
| Risk | 2 | 2014 | 371 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 261 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 72 | 0.050 |
Why?
|
| Adrenalectomy | 1 | 2022 | 24 | 0.050 |
Why?
|
| Hematoma | 1 | 2022 | 74 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 21 | 0.050 |
Why?
|
| Genotype | 2 | 2014 | 644 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2023 | 136 | 0.050 |
Why?
|
| Comorbidity | 2 | 2016 | 1084 | 0.050 |
Why?
|
| Suicide | 1 | 2003 | 123 | 0.050 |
Why?
|
| Age of Onset | 1 | 2021 | 173 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2020 | 43 | 0.040 |
Why?
|
| Ezetimibe | 1 | 2019 | 6 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2019 | 34 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 63 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2021 | 200 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2020 | 223 | 0.040 |
Why?
|
| Health Facilities | 1 | 2018 | 43 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 95 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 132 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2019 | 306 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 842 | 0.040 |
Why?
|
| Income | 1 | 2019 | 160 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 684 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2018 | 84 | 0.040 |
Why?
|
| Burnout, Professional | 1 | 2019 | 122 | 0.040 |
Why?
|
| Minority Groups | 1 | 2018 | 140 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2018 | 148 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 434 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 354 | 0.030 |
Why?
|
| Poverty | 1 | 2019 | 286 | 0.030 |
Why?
|
| Cholesterol | 1 | 2018 | 255 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 720 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 30 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 9 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2016 | 46 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 34 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2352 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 125 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 149 | 0.030 |
Why?
|
| Paris | 1 | 2015 | 4 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 120 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 328 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 49 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2014 | 18 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 666 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 78 | 0.030 |
Why?
|
| Aging | 1 | 2020 | 722 | 0.030 |
Why?
|
| Social Class | 1 | 2015 | 123 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 787 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 64 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 180 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 299 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 114 | 0.030 |
Why?
|
| Etidronic Acid | 1 | 2013 | 3 | 0.030 |
Why?
|
| Contraindications | 1 | 2013 | 45 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 449 | 0.030 |
Why?
|
| Alendronate | 1 | 2013 | 14 | 0.030 |
Why?
|
| 5-Methylcytosine | 1 | 2013 | 20 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 208 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 126 | 0.030 |
Why?
|
| Child | 1 | 2003 | 4298 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 256 | 0.030 |
Why?
|
| Asbestos | 1 | 2013 | 12 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 61 | 0.030 |
Why?
|
| Leptin | 1 | 2013 | 78 | 0.030 |
Why?
|
| Alleles | 1 | 2014 | 425 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 119 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 403 | 0.030 |
Why?
|
| Epigenomics | 1 | 2013 | 54 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 134 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 219 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2016 | 485 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 1155 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 306 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 445 | 0.020 |
Why?
|
| Viral Load | 1 | 2011 | 228 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 580 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2013 | 314 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 563 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 366 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 158 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1224 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 595 | 0.020 |
Why?
|
| Mice | 2 | 2014 | 10249 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 673 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1036 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 571 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 104 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 67 | 0.020 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2008 | 28 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1220 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1100 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 142 | 0.020 |
Why?
|
| Outpatients | 1 | 2008 | 131 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 442 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2007 | 312 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 454 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 808 | 0.010 |
Why?
|